Certolizumab Pegol

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1420 publications

Tumor Necrosis Factor-Alpha Inhibitors: Oral Health and Orthodontic Considerations.

Tumor Necrosis Factor-Alpha Inhibitors: Oral Health and Orthodontic Considerations.

Journal: Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995)

Published: October 13, 2026

Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.

Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.

Journal: EULAR rheumatology open

Published: August 01, 2026

Case Report: Certolizumab pegol as a potential rescue option for severe erythema multiforme associated with pustular psoriasis during pregnancy.

Case Report: Certolizumab pegol as a potential rescue option for severe erythema multiforme associated with pustular psoriasis during pregnancy.

Journal: Frontiers in medicine

Published: July 09, 2026

Association Between Systemic TNF-α Inhibitor Use and Risk of Primary Open-Angle Glaucoma.

Association Between Systemic TNF-α Inhibitor Use and Risk of Primary Open-Angle Glaucoma.

Journal: American journal of ophthalmology

Published: June 18, 2026

Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study.

Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study.

Journal: Biomolecules

Published: June 16, 2026

Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.

Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.

Journal: Dermatology and therapy

Published: June 15, 2026

Certolizumab Pegol for Hidradenitis Suppurativa: A Systematic Review.

Certolizumab Pegol for Hidradenitis Suppurativa: A Systematic Review.

Journal: Journal of the American Academy of Dermatology

Published: May 20, 2026

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival.

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival.

Journal: Dermatology and therapy

Published: May 19, 2026

Vitiligo onset following anti-inflammatory biological therapy: a scoping review.

Vitiligo onset following anti-inflammatory biological therapy: a scoping review.

Journal: Frontiers in immunology

Published: May 12, 2026

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.

Journal: RMD open

Published: May 06, 2026

Decoding biological drug names in dermatology: The post-2022 WHO nomenclature revision and its implications for clinical practice.

Decoding biological drug names in dermatology: The post-2022 WHO nomenclature revision and its implications for clinical practice.

Journal: Journal of the American Academy of Dermatology

Published: May 01, 2026

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.

Journal: Frontiers in pharmacology

Published: April 26, 2026

Showing 1-12 of 1,420

Last Updated: 11/08/2026